Safety Study of Elvucitabine in HIV-1 Subjects

Completed · Phase 2

Conditions studied: HIV Infections

In brief

The purpose of this 28 day study is to assess the viral kinetics and safety of elvucitabine.

Key facts

Study ID

NCT00405249

Run by

Thomas Jefferson University

People needed

5

Starts

2006-09-01

Expected to finish

2006-11-01

Last updated by the study team

2009-02-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV infected, clinically stable, adults
• HIVRNA 5000 -150,000, CD4 100
• Genotypically documented M184V variant
• Receiving stable ART.

You may not qualify if…

• Hep B
• HIV-1 genotype for 4 protease inhibitors
• HIV-1 genotype positive for 2 NNRTI mutations
• Previous therapy with system myelosuppressive potential within 3 months of study start
• Use of Epogen or Neupogen
• History of cirrhosis
• Alcohol or drug dependence
• Inability to tolerate oral medication
• Women who are pregnant or breast feeding

Where it is running

• Thomas Jefferson University — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.